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Abstract 
This manuscript described the synthesis and biological activity of novel nitro 
substituted E-2-styryl-benzimidazoles and E-2-(2-benzimidazolyl)-3-phenylacrylonitriles and 
nitro and amino substituted benzimidazo[1,2-a]quinolines (4-5, 6-11, 17-20 and 21-32). All of 
the compounds showed significant growth inhibitory effect towards five tumor cell lines, 
whereby the IC50 concentrations of 11, 20, 28, 29, 30, 32 are in the low micromolar range. 
The DNA binding experiments did not show significant affinity of two selected compounds 
towards ds-DNA. The flow cytometry analysis of potential cell cycle perturbations after the 
treatment with compounds 9, 11, 25 and 29 demonstrated that all of the compounds (5 µM ≈ 
IC50) significantly delayed the progression through G1 phase, as demonstrated by the 
accumulation of cells in G1 phase, accompanied with the reduction of the cell number in the 
cells in S phase, which does not point to DNA damage as the main mechanism of action. 
Also, fluorescence microscopy study showed cytoplasmic distribution of the compounds, 
demonstrating that DNA is not the primary target of compounds. Thus, considerable 
antiproliferative effects of studied compounds are due to interactions with other biological 
targets within cells. 
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Introduction  
Since classical chemotherapy, which uses small molecules or bioactive natural 
products, is still the mainstay of cancer treatment, there has been a tremendous growth in 
recent years in the number and types of new heterocyclic anticancer agents with an emphasis 
on creating new DNA active drugs. DNA molecule is one of the principal targets for 
anticancer agents designed to block the proliferation of cancer cells, since DNA synthesis and 
replication are important processes for cellular growth.1 Understanding of the molecular basis 
for cytotoxicity by anticancer agents is very important for the development of novel, more 
selective and efficient agents with greater specificity of action.2,3,4 The benzimidazole unit 
which has a structural similarity with purine, is also the key building block for a variety of 
derivatives that are known to play crucial roles in the functions of a number of biologically 
important molecules. Besides, benzimidazoles represent the major backbone of numerous of 
synthetic medical and biochemical agents possessing different chemical and pharmacological 
features which impart them diverse biological properties like anticancer,5,6,7 antiviral,8,9 
antibacterial,10,11 antifungal,12 antihistaminic13 and anticonvulsant activity.14  
As a part of our continuing search for potential anticancer agents related to 
benzimidazole derivatives, we have recently reported on the synthesis, cytostatic evaluation, 
DNA/RNA interaction study and proteomic profiling of a series of amidino-substituted 
heterocyclic benzimidazoles and benzimidazo[1,2-a]quinolines.15,16 Biological study 
confirmed the anticancer potential of this class of compounds, especially that of positively 
charged analogues of benzimidazo[1,2-a]quinolines which intercalate into ds DNA or RNA. 
Thus, the most promising 2-imidazolynil amidino substituted compounds inhibited tumor 
growth, caused severe disturbance of the cell cycle, impairment in mitotic progression, and 
inhibited topoisomerases, which was related to their high DNA binding capacity. Recent 
publications also showed that nitro substituted benzazolo[3,2-a]quinolinium derivatives are 
potential antineoplastic agents that interacts with DNA by intercalation and that 
topoisomerase II is an important target for their biological action.17,18 It was also concluded 
that the cytotoxic properties of these compounds appeared to be more dependent on their 
ability to inhibit topoisomerase II than on DNA binding affinity or intercalation.19 Substituted, 
earlier prepared benzimidazo[1,2-a]quinoline-6-carbonitriles exerted pronounced 
antiproliferative activity with the cyano moiety important for the activity but not the 
selectivity of tested compounds.  
Some of above mentioned compounds also showed significant interaction with ct-DNA, 
supporting the fact that their antitumor activity could partially be the consequence of DNA-
binding.20   
Prompted by the results from the previously reported studies, we set out to explore and 
synthesize novel acyclic nitro 4, 5, 17-20 and cyclic nitro 6, 7, and 21-24 and amino 8-9 and 
26-28 substituted benzimidazole[1,2-a]quinolines with the substituents on the different 
positions of the condensed tetracyclic ring. The hydrochloride salts 10-11 and 29-32 were 
prepared to improve their solubility in water (Figure 1). Newly synthesized compounds were 
tested for their antiproliferative activity on the panel of several human tumor cell lines while 
study of interaction with calf thymus DNA (ctDNA) was performed for compounds 11 and 25.  
R1
Cl
N
H
N
4    R1=NO2,  R2=H, R3=H
5    R1=NO2,  R2=NO2, R3=H
17  R1=NO2,  R2=H, R3=CN
18  R1=H,  R2=NO2, R3=CN
19  R1=NO2,  R2=NO2, R3=CN
20  R1=NO2,  R2=CH3, R3=CN
R2R3
N
N
R1
R3
24  R1=NO2,  R2=CH3, R3=CN
25  R1=NH2,  R2=H, R3=CN
26  R1=H,      R2=NH2, R3=CN
27  R1=NH2,  R2=NH2, R3=CN
28  R1=NH2,  R2=CH3, R3=CN
29  R1=NH3
+Cl-,  R2=H, R3=CN
30  R1=H,      R2=NH3
+Cl-, R3=CN
31  R1=NH3
+Cl-,  R2=NH3
+Cl-, R3=CN
32  R1=NH3
+Cl-,  R2=CH3, R3=CN
6    R1=NO2,  R2=H, R3=H
7    R1=NO2,  R2=NO2, R3=H
8    R1=NH2,  R2=H, R3=H
9    R1=NH2,  R2=NH2, R3=H
10  R1=NH3
+Cl-,  R2=H, R3=H
11  R1=NH3
+Cl-,  R2=NH3
+Cl-, R3=H
21  R1=NO2,  R2=H, R3=CN
22  R1=H,      R2=NO2, R3=CN
23  R1=NO2,  R2=NO2, R3=CN
R2
 
Figure 1. 
 
2. Results and Discussion 
2.1 Chemistry 
All newly prepared compounds (Figure 1) were synthesized according to the two main 
procedures shown in Scheme 1, by the conventional methods of organic synthesis for the 
preparation of similar heterocyclic compounds starting from the corresponding o-
phenylenediamines 1-2. In the cyclocondensation reaction between the E-3-(2-chloro-5-
nitrophenyl)acrylic acid 3 with o-phenylenediamines 1-2 in polyphosphoric acid, E-2-styryl-
benzimidazoles 4-5 were prepared. In the reaction between o-phenylenediamines 1-2 with 2-
cyanoacetamide corresponding substituted 2-cyanomethylbenzimidazoles 12-14 were 
prepared. They gave in the reaction of aldol condensation with aromatic aldehydes 15-16 
substituted E-2-(2-benzimidazolyl)-3-phenylacrylonitriles 17-20.  
 
Cl
R1
R1
Cl
N
H
N
N
N
R1
N
N
R1
1. SnCl2×2H2O/MeOH, HCl
2. EtOH, HClg
sulfolane
PPA
4  R1=NO2,  R2=H
5  R1=NO2,  R2=NO2
R2
1  R2=H
2  R2=NO2
R2
3  R1=NO2
8  R1=NH2,  R2=H
9  R1=NH2,  R2=NH2
6  R1=NO2,  R2=H
7  R1=NO2,  R2=NO2
  10  R1=NH3
+Cl-,  R2=H
  11  R1=NH3
+Cl-,  R2=NH3
+Cl-
COOH
NH2
NH2
CNCH2CONH2
N
H
N CNR2
12  R2=NO2
13  R2=H
14  R2=CH3
R1
Cl NC
N
H
N
N
N
R1
CN
N
N
R1
CN
1. SnCl2×2H2O/MeOH, HCl
2. EtOH, HClg
sulfolane
17  R1=NO2,  R2=H
18  R1=H,      R2=NO2
19  R1=NO2,  R2=NO2
20  R1=NO2,  R2=CH3
R2
25  R1=NH2,  R2=H
26  R1=H,      R2=NH2
27  R1=NH2,  R2=NH2
28  R1=NH2,  R2=CH3
21  R1=NO2,  R2=H
22  R1=H,   R2=NO2
23  R1=NO2,  R2=NO2
24  R1=NO2,  R2=CH3
29  R1=NH3
+Cl-,  R2=H
30  R1=H, R2=NH3
+Cl-
31  R1=NH3
+Cl-,  R2=NH3
+Cl-
32  R1=NH3
+Cl-,  R2=CH3
piperidine
EtOH
Cl
CHOR1
15  R1=NO2
16  R1=HR2
R2
R2
R2
Scheme 1. 
Cyclic nitro substituted derivatives of benzimidazo[1,2-a]quinolines 6-7 and 
benzimidazo[1,2-a]quinolines-6-carbonitriles 21-24 were prepared by the thermal reaction 
using sulfolane for dehydrohalogenation cyclization at 280 °C followed by UV/Vis 
spectroscopy.21 Acyclic derivatives 5 and 18-20 with substituents on the benzimidazole nuclei 
gave in the cyclization reaction two inseparable regioisomers. Amino substituted cyclic 
derivatives 8-9 and 25-28 were prepared from nitro substituted compounds by reduction with 
SnCl2x2H2O in MeOH and concentrated HCl. The hydrochloride salts of amino substituted 
benzimidazo[1,2-a]quinolines 10-11 and 29-32 were prepared with HClgas in order to ensure 
better solubility.  
All structures of novel E-2-styryl-benzimidazoles 4-5, E-2-(2-benzimidazolyl)-3-
phenylacrylonitriles 17-20, benzimidazo[1,2-a]quinolines 6-11 and benzimidazo[1,2-
a]quinolines-6-carbonitriles 21-32 were determined by the NMR analysis based on the 
analysis of H-H coupling constants as well as chemical shifts. In 1H NMR spectra of E-2-
styryl-benzimidazoles 4-5 besides all other aromatic protons, two doublets for trans-ethylenic 
protons with coupling constants of ~16.5 Hz can be observed. Singlet of the NH group of 
benzimidazole nuclei is placed around ~13 ppm. The photocyclization reaction leads to a 
downfield shift of the signals of the ethylenic protons and most other aromatic protons as well 
as disappearance of the NH group at the benzimidazole nuclei, thus confirming the cyclic 
structure formation. In 1H NMR spectra doublets for two protons on quinoline ring, with 
coupling constants ~9.5 Hz, can be observed and these values are characteristic for this type 
of fused compounds. 
 
2.2 Interaction of compounds 11 and 25 with ct-DNA in an aqueous medium  
2.2.1. UV/Vis, fluorimetric and CD titrations  
Since application of spectrophotometric methods is necessary for DNA binding studies 
of compounds 11 and 25, their aqueous buffered solutions were characterized by means of 
electronic absorption (UV/Vis) and fluorescence emission spectroscopy (Table 1). Stock 
solution of compound 11 was prepared in water (c(11) = 1.05 × 10-3 mol dm-3) while stock 
solution of compound 25 was prepared, due to the poor solubility in water, in DMSO (c(25) = 
1.68 × 10-3 mol dm-3). Small aliquots of DMSO stock solution of compound 25 were added 
into the aqueous medium, provided that DMSO content in experiments was less than 1%. 
Stock solutions were stable over prolonged periods of time. Absorbencies of aqueous buffered 
solutions are proportional to their concentrations up to 1.52 × 10-5 mol dm-3 (11) and 2.5 × 10-
5 mol dm-3 (13) indicating that there is no significant intermolecular stacking which should 
give rise to hypochromic effects. Studied compounds 11 and 25 exhibited strong fluorescence 
emission with maximum at 521 nm and 562 nm. Fluorescence emissions of 11 and 25 were 
proportional to their concentration in the range from 4×10-8 mol dm-3 to 2×10-6 mol dm-3, and 
their excitation spectra were in concordance with the corresponding absorption spectra. 
Absorption maxima, corresponding molar extinction coefficients () and fluorescence 
emission maxima are presented in Table 1.  
 
Table 1. Electronic absorption maxima, molar extinction coefficients and fluorescence emission 
maxima of studied compounds in sodium cacodylate buffer (I = 0.05 mol dm-3, pH = 7) 
 Absorption maxima Fluorescence emission 
Comp.   max / nm    103 / dm3 mol-1 cm-1 max / nm 
11 
353 
261 
251 
23.14 
20.93 
23.13 
 
521 
 
25 
347 
273 
10.18 
37.81 
562 
                              
Addition of ctDNA to a buffered solution of compounds 11 and 25 resulted in 
bathochromic and hypochromic effects of UV/Vis spectra of studied compounds (Figure 2). 
as follows: H (11, 352 nm) = 44%, Δ(11, 352 nm) = 20 nm and H (25, 347 nm) = 28%, 
Δ(25, 347 nm) = 13 nm, H (25, 362 nm) = 17%, Δ(25, 362 nm) = 14 nm (H 
(hypochromic effect) = (Abs(compound) - Abs(complex)) / Abs(compound)) x 100; values 
Abs(complex) estimated by non-linear extrapolation;  (shift of the absorbance maximum) = 
(complex) - ( compound)). 
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 Figure 2. A) The UV/Vis titration of 11 (c = 2.0 × 10-5 mol dm-3) with ct-DNA; B) 
spectroscopic changes at max=353 nm as a function of ct-DNA concentration; C) The UV/Vis 
titration of 25 (c = 1.9 × 10-5 mol dm-3) with ct-DNA; B) spectroscopic changes at max=348 
nm as a function of ct-DNA concentration; 
 
 
Addition of ct-DNA to a buffered compounds solution strongly quenched fluorescence 
intensity of 11 while enhanced fluorescence intensity of 25 (Figure 3).  
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Figure 3. A) Changes in fluorescence spectrum of 11 (c =3.3 ×10-7 mol dm-3) upon titration 
with ct-DNA (c =1.00×10-3 mol dm-3); B) Dependence of 11 emission at  =524 nm on c(ct-
DNA); C) Changes in fluorescence spectrum of 25 (c =1.12 ×10-6 mol dm-3) upon titration 
with ct-DNA (c =2.00×10-3 mol dm-3); B) Dependence of 25 emission at  =559 nm on c(ct-
DNA); All experiments were carried out at pH=7.0, (buffer sodium cacodylate I =0.05 mol 
dm-3). 
 
Affinity of compounds toward ct-DNA and density of binding was calculated by 
processing of UV/Vis and fluorescence titration data according to Scatchard equation (Table 
2).22  
 
 
Table 2. Binding constants (logKs)a calculated from the UV/vis and fluorimetric titrations with ctDNA 
at pH = 7 (buffer sodium cacodylate, I = 0.05 mol dm-3). 
Compound 
Fluorescence        UV/vis 
log Ks log Ks 
11 4.8 4.6 
25 5.5 5.1 
a Processing of titration data by Scatchard equation gave Scatchard ratios n[bound compound]/ [polynucleotide] = 
0.1 - 0.2, for better comparison binding constants were re-calculated for fixed ratio n[bound compound]/ 
[polynucleotide] = 0.2. 
 
Since CD spectroscopy is a highly sensitive method toward conformational changes in the 
secondary structure of polynucleotides, we have chosen it to get insight into the changes of 
polynucleotide properties induced by small molecule binding.23,24 Studied compounds are 
achiral and therefore do not possess intrinsic CD spectrum. The addition of studied 
compounds 11 and 25 to the ctDNA resulted in small increase of CD band at 275 nm, which 
suggested small changes in the helical structure of DNA upon binding (Supplementary 
Material, Fig. S1). The absence of the measurable induced (ICD) band at > 300 nm pointed 
toward non-homogenous orientation of bound molecules of 11 and 25 in respect to DNA 
helical axis.24  
 
2.2.2. Thermal Denaturation Experiments and Viscometry 
In the thermal denaturation experiments addition of compound 11 didn’t yield any 
measurable effect on the Tm value of ctDNA while addition of 25 yielded weak but 
measurable stabilization of the ctDNA double helix (Table 3). 
Table 3. Tm valuesa (°C) of ct-DNA upon addition of different ratios                                                             
br of 11 and 25 at pH = 7.0 (buffer sodium cacodylate, I = 0.05 mol dm-3). 
br 11 25 
0.1 0 0.9 
0.2 0 1.9 
0.3 0 0.2 
aError in Tm :  0.5°C; b r = [compound] / [polynucleotide]. 
Viscometry experiments (Supplementary Material) yielded values of (11) = 0.88 and (25) 
=0.40, former value differing from the value obtained for ethidium bromide ((EB) = 0.90) 
by the error of the method (  0.1). Obtained results support intercalation of only charged 
derivative 11, while its neutral analogue 25 most likely agglomerates along DNA double 
helix. 
 
2.2.3. Discussion of Interaction of compounds 11 and 25 with ctDNA 
Viscometry results showed that compound 11 (α=0.88 ± 0.1) elongated ct-DNA 
similarly to referent intercalator (EB, α=0.90 ± 0.1), while addition of 25 yielded only 
negligible DNA elongation (α=0.4 ± 0.1) accompanied by strongly non-linear effect of the 
viscometry increase. Obtained results support intercalation of only charged derivative 11, 
while its neutral analogue 25 most likely agglomerates along DNA double helix. However, 11 
does not show any impact on ctDNA thermal denaturation (ΔTm = 0), which is not common 
for intercalators. Possible explanation is that bulky amino substituents hamper complete 
insertion of the large condensed aromatic moiety between DNA basepairs, whereby partial 
intercalation does elongate DNA similar to EB (viscometry) but yields very weak stabilization 
of DNA double helix, very weak ICD effect and binding constant (logKs=5.1) an order of 
magnitude lower than one could expect from the aromatic surface (for instance under the 
same experimental conditions fluorimetric titration of EB with ctDNA gave logKs=6).  
 
2.3. Biological Results and Discussion  
All of the compounds showed significant growth inhibitory effect towards five tumor 
cell lines, four of which were derived from solid tumors and one leukemia cell line (Table 3). 
Compounds 4, 5, 23, 24 exerted moderate, while 11, 20, 28, 29, 30, 32 strong antiproliferative 
activity (in the low micromolar range). There is in general no significant difference in 
sensitivity between cell lines, except compound 4, which showed interesting selectivity 
towards HCT 116 cells, while being modestly active towards other cell lines). It should be 
noted though, that compounds 4-6, 20, 23-25, 29 and 30 precipitated at the maximal tested 
concentration, which might hamper their full effect. Since there is in general no significant 
difference in the IC50 concentrations between the activity of tested compounds, and the DNA 
binding experiments did not show significant affinity of two selected compounds towards ds-
DNA (diamino substituted derivative 11 as dihydrochloride salt and amino-cyano substituted 
derivative 25), we attempted the flow cytometry analysis of potential cell cycle perturbations 
after the treatment with diamino-substituted derivative 9 and its dihydrochloride analogue 11 
and their mono-substituted analogues (25 and 29, respectively) (Table 4). The results 
demonstrated that all of the compounds (5 µM ≈ IC50) significantly delayed the progression 
through G1 phase, as demonstrated by the accumulation of cells in G1 phase, accompanied 
with the reduction of the cell number in the cells in S phase, 24 hours after the addition of the 
compounds. Even more drastic S phase reduction was obtained after the treatment with higher 
concentration (10 µM, data not shown). This effect diminished after 48 hours; predominantly 
in the cells treated with 25 and 29, while the most pronounced effect was obtained with the 
charged dihydrochloride derivative 11. These results again suggest that the DNA isn’t the 
main target of the tested compounds, although some affinity of the charged compounds 
towards DNA was demonstrated. Namely, contrary to here-presented results, intercalators 
induce strong G2/M phase delay/arrest, as also demonstrated in our previously-published 
studies (15,16). We therefore performed fluorescence microscopy study with the compounds 11 
and 29 to check the intracellular distribution of the compounds in the tumor cells. The results 
confirm that the compounds are not localized in the nucleus, but are distributed throughout the 
cytoplasm both after 2 h and 24 h (Figure 4 and data not shown). Certain differences, 
however, can be observed between the localization of the two compounds; compound 29 is 
localized more distinctively near nucleus, pointing to possible colocalization with 
endoplasmatic reticulum, while compound 11 is evenly distributed, forming small 
cytoplasmic aggregates, which could suggest their localization in the lysosomes, or 
endosomes.  
 
 
 
 
 
 
 
 Table 3. IC50 values (in μM) a,b 
Compound 
Cell lines 
 
MOLT-4 HCT 116 SW 620  MCF-7 H 460 
4 >100 4±0.2 28±2 32±19 >100 
5 5±5 21±13 16±2 19±2 13±1 
6 3±1 6±3 6±1 4±1 8±0.2 
9 11±2 4±3 3±2 8±0.3 3±1 
11 5±1 4±3 3±1 4±2 3±1 
18 6±5 16±4 14±1 10±0.2 17±0.3 
19 3±1 5±0.2 20±1 19±9 15±3 
20 5±2 3±1 4±3 3±2 19±5 
22 24±22 5±1 7±1 8±2 3±1 
23 4±2 4±2 38±14 10±0.2 11±1 
24 43±25 6±3 7±4 ≥100 5±0.1 
25 c 6±3 4±1 4±1 4±3 3±0.1 
26c ≥10 4±2 5±3 ≥10 4±0.03 
27 11±0.4 6±1 9±2 3±1 5±2 
28 17±12 11±3 10±6 11±0.2 9±2 
29 2±0.1 3±0.04 6±2 4±2 2±0.2 
30 3±2 4±1 4±0.1 4±2 2±0.3 
31 5±4 5±3 4±2 3±2 4±3 
32 8±5 4±3 4±1 6±3 3±0.1 
a IC50; the concentration that causes 50% growth inhibition 
b Compounds were dissolved in DMSO to a stock solutions concentration of 1 to 4×10-2 M. However, the 
precipitation in the cell culture medium at 10-4 M after 72 hours was observed for compounds 4-6, 20, 23-25, 29 
and 30. 
c The highest tested concentration was 10µM. 
 
 Table 4. The effects of 25, 29, 9 and 11 at 5 µM on the cell cycle distribution of HCT116 
cells after the 24- and 48-hours treatments. The numbers represent the percentages of cells in 
respective cell cycle phase (G1, S and G2/M), along with the percentage of cells in the subG1 
(dead cells) obtained by flow cytometry.  
 
Treatment 
Percentage of cells (%) 
SubG0/G1 G0/G1 S G2/M 
24h 
control 3 40 39 21 
25 6 62 20 18 
29 4 55 20 25 
9 1 49 33 18 
11 1 65 14 21 
48h 
control 1 40 35 25 
25 3 47 25 28 
29 4 45 31 24 
9 2 54 25 21 
11 2 60 23 17 
 
 
a) 
 
b) 
 
 
Figure 4. Fluorescent microscopy images of H 460 cells treated with compound 29 (a) 100 
µM for 2h; and compound 11 (b) 100 µM for 2h; both showing predominately cytoplasmic 
distribution of the compounds. 
 
 
 
 3. Conclusions  
 In this work we have presented the synthesis of novel acyclic nitro substituted 
E-2-styryl-benzimidazoles 4-5, E-2-(2-benzimidazolyl)-3-phenylacrylonitriles 17-20 and 
cyclic substituted benzimidazole[1,2-a]quinolines 6-11 and 21-32. Detailed studies of two 
chosen compounds (11 and 25) revealed that they only weakly interact with ds-DNA, 
whereby 11 partially intercalates and 25 just agglomerates along DNA double helix. 
Accordingly, biological studies (impact on the cell cycle and fluorescence microscopy) also 
showed that DNA is not the primary target of compounds. Thus, considerable antiproliferative 
effects of studied compounds are due to interactions with other biological targets within cells. 
 
4. Experimental 
 
4.1. Chemistry 
 
4.1.1. General methods 
 
All chemicals and solvents were purchased from commercial suppliers. Melting points 
were recorded on an Original Keller Mikroheitztisch apparatus (Reichert, Wien) and Büchi 
535. 1H and 13C NMR spectra were recorded on a Varian Gemini 300 or Varian Gemini 600 
at 300, 600 and 150 and 75 MHz, respectively. All NMR spectra were measured in DMSO-d6 
solutions using TMS as an internal standard. Chemical shifts are reported in ppm (δ) relative 
to TMS. IR spectra were recorded on FTIR-ATR and Perkin-Elmer Spectrum 1 
spectrophotometers. Elemental analysis for carbon, hydrogen and nitrogen were performed on 
a Perkin-Elmer 2400 elemental analyzer and a Perkin-Elmer, Series II, CHNS Analyzer 2400. 
Where analyses are indicated only as symbols of elements, analytical results obtained are 
within 0.4% of the theoretical value. All compounds were routinely checked by TLC with 
Merck silica gel 60F-254 glass plates.   
 
4.1.2. General method for preparation of compounds 4-5 
A mixtures of equimolar amounts of corresponding 3-(2-chloro-5-nitrophenyl)acrylic 
acid 3 and 1,2-phenylenediamines 1-2 together with PPA (10 g) were heated at 180 °C for 3 
hours. The cooled mixture was poured into ice-water (200 ml) and the resulting solution was 
treated with 25 % NH3.H2O to pH 9. The suspension was filtered off and the crude product 
was washed with water to pH 7 and recrystallizated from ethanol to obtain E-2-styryl-
benzimidazoles 4-5.  
4.1.2.1. E-{2-[2-(2-chloro-5-nitrophenyl)-ethenyl]}benzimidazole 4 
 Compound 4 was prepared using above described method, from 3-(2-chloro-5-
nitrophenyl)acrylic acid 3 (1.00 g, 4.40 mmol) and 1,2-phenylenediamine 1 (0.48 g, 4.40 
mmol) to obtain a light brown powder (0.67 g, 51 %). mp 133-136 °C; IR (diamond) υ/cm-1: 
3074, 1570, 1520; 1H NMR (600 MHz, DMSO-d6): δ = 12.85 (bs, NHarom., 1H), 8.70 (d, 
J=2.67 Hz, Harom., 1H), 8.18 (dd, J1=2.70 Hz, J2=8.82 Hz, 1H), 7.97 (d, J=16.38 Hz, Harom., 
1H), 7.85 (d, J=8.76 Hz, Harom., 1H), 7.66 (d, J=7.76 Hz, Harom., 1H), 7.55 (bs, Harom., 1H), 7.52 
(d, J=16.32 Hz, Harom., 1H), 7.22 (d, J=8.34 Hz, Harom., 2H);  
13C NMR (75 MHz, DMSO-d6): δ 
= 150.23 (s), 147.42 (s), 139.29 (s), 135.61 (s,2C), 131.80 (d,2C), 127.71 (d,2C), 124.54 (d), 
123.94 (d,2C), 122.20 (d,2C); elemental analysis calcd. (%) for C15H10ClN3O2: C 60.11, H 
3.36, N 14.02; found C 60.33, H 3.50, N 14.09. 
4.1.2.2. E-{2-[2-(2-chloro-5-nitrophenyl)-ethenyl]}5(6)-nitrobenzimidazole 5 
Compound 5 was prepared using above described method, from 3-(2-chloro-5-
nitrophenyl)acrylic acid 3 (1.00 g, 4.40 mmol) and 4-nitro-1,2-phenylenediamine 2 (0.67 g, 
4.40 mmol) to obtain a brown powder (0.42 g, 27 %). mp >300 °C; ; IR (diamond) υ/cm-1: 
3358, 1613, 1520, 1338;  1H NMR (300 MHz, DMSO-d6): δ = 8.74 (d, J=2.58 Hz, Harom., 1H), 
8.50 (d, J=2.10 Hz, Harom., 1H), 8.21 (dd, J1=2.61 Hz, J2=8.82 Hz, Harom., 1H), 8.13 (dd, 
J1=2.30 Hz, J2=9.01 Hz, Harom., 1H), 8.08 (d, J=16.47 Hz, Harom., 1H), 7.86 (d, J=8.82 Hz, 
Harom., 1H), 7.77 (d, J=8.91 Hz, Harom., 1H), 7.60 (d, J=16.29 Hz, Harom., 1H); 
13C NMR (75 
MHz, DMSO-d6): δ = 154.75 (s), 149.41 (s), 147.47 (s), 147.27 (s), 143.18 (s), 139.60 (s), 
135.00 (s), 131.80 (d), 130.67 (d), 124.95 (d), 122.93 (d), 122.84 (d), 122.34 (d),122.17 (d), 
118.57 (d); elemental analysis calcd. (%) for C15H9ClN4O4: C 52.26, H 2.63, N 16.25; found 
C 52.44, H 2.89, N 16.43. 
 
4.1.3. General method for preparation of compounds 17-20 
Solution of equimolar amounts of 2-cyanomethylbenzimidazole derivatives 12-14, 
corresponding heteroaromatic aldehydes and few drops of piperidine in absolute ethanol, were 
refluxed for 2-3 hours. After reaction mixture was cooled to the room temperature, the crude 
product was filtered off and recrystallized from ethanol. 
4.1.3.1. 2-(2-Benzimidazolyl)-3-(2-chloro-5-nitrophenyl)acrylonitrile 17      
 Compound 17 was prepared from 13 (0.69 g, 4.4 mmol) and 2-chloro-5-nitro-
benzaldehyde 15 (0.81 g, 4.4 mmol) in absolute ethanol (10 ml) after refluxing for 2.5 hours 
and recrystallization from ethanol to yield 1.16 g (66%) of brown crystals; m.p. >300 °C; IR 
(diamond) υ/cm-1: 3271, 2235, 1603, 1514; 1H NMR (600 MHz, DMSO-d6): δ = 13.41 (s, 1H, 
NHbenzim.), 8.99 (d, 1H, J=2.67 Hz), 8.50 (s, 1H, Harom.), 8.38 (dd, 1H, J1=2.70 Hz, J2=8.85 
Hz), 7.98 (d, 1H, J=8.85 Hz, Harom.), 7.76 (d, 1H, J=7.62 Hz, Hbenzim.), 7.60 (d, 1H, J=7.77 Hz, 
Hbenzim.), 7.35 – 7.27 (m, 2H, Hbenzim.);  13C NMR (75 MHz, DMSO-d6): δ = 147.20 (s), 147.17 
(s), 146.93 (s), 141.15 (s), 139.59 (d), 133.25 (s), 132.33 (d, 2C), 132.17 (s), 132.09 (d), 
127.37 (d, 2C), 125.12 (d, 2C), 115.68 (s), 109.72 (s); elemental analysis calcd. (%) for 
C16H9ClN4O2: C 59.18, H 2.79, N 17.25; found C 59.33, H 2.93, N 17.45. 
 
4.1.3.2. 2-[2-(5(6)-nitro)benzimidazolyl)-3-(2-chlorophenyl)acrylonitrile 18  
 Compound 18 was prepared from 12 (2.00 g,  9.9 mmol) and 2-chlorobenzaldehyde 16 
(1.40 g,  9.9 mmol)  in absolute ethanol (10 ml) after refluxing for 2 hours and 
recrystallization from ethanol to yield 2.52 g (78%) of brown crystal; m.p. 209-213 °C; IR 
(diamond) υ/cm-1: 3228, 2239, 1508, 1336, 1054; 1H NMR (300 MHz, DMSO-d6): δ = 13.95 
(bs, NHarom., 1H), 8.64 (s, Harom, 1H), 8.56 (s, Harom, 1H), 8.19 (dd, J1=8.93 Hz, J2=2.24 Hz, 
Harom, 1H), 7.96 (d, J=8.55 Hz, Harom, 1H), 7.83 (d, J=8.91 Hz, Harom, 1H), 7.71 (dd, J1=7.68 
Hz, J2=2.19 Hz, Harom, 1H), 7.64-7.56 (m, Harom, 2H);  
13C NMR (75 MHz, DMSO-d6): δ = 
155.75 (d), 151.48 (s), 144.04 (d), 143.78 (s), 136.38 (s), 134.56 (s), 133.66 (d), 133.10 (s), 
131.31 (s), 130.62 (d), 130.26 (d), 128.31 (d), 119.31 (d), 115.53 (s), 113.70 (d), 106.35 
(s);elemental analysis calcd. (%) for C16H9ClN4O2: C 59.18, H 2.79, N 17.25; found C 59.34, 
H 2.96, N 17.01. 
4.1.3.3. 2-[2-(5(6)-nitro)benzimidazolyl)-3-(2-chloro-5-nitrophenyl)acrylonitrile 19  
 Compound 19 was prepared from 12 (0.92 g,  4.9 mmol) and 2-chloro-5-nitro-
benzaldehyde 15 (1.00 g,  4.9 mmol)  in absolute ethanol (10 ml) after refluxing for 2 hours 
and recrystallization from ethanol to yield 0.30 g (22%) of brown powder.; m.p. 300 °C; ; IR 
(diamond) υ/cm-1: 2230, 1606, 1527, 1341; 1H NMR (300 MHz, DMSO-d6): δ = 9.01 (d, 
J=2.58 Hz, Harom., 1H), 8.62 (s, Harom., 1H), 8.57 (d, J=2.07 Hz, Harom., 1H), 8,42 (dd, J1=2.67 
Hz, J2=8.87 Hz, Harom., 1H), 8.18 (dd, J1=2.22 Hz, J2=8.94 Hz, Harom., 1H), 8.00 (d, J=8.88 Hz, 
Harom., 1H), 7.83 (d, J=8.94 Hz, Harom., 1H); 
13C NMR (75 MHz, DMSO-d6): δ = 151.38 (s), 
146.80 (s), 141.17 (d), 143.70 (s), 143.12 (s), 139.39 (s), 132.53 (s), 132.10 (d), 127.39 (d), 
124.74 (d), 119.26 (d), 115.63 (d), 115.13 (s), 113.61 (d), 108.80 (s); elemental analysis calcd. 
(%) for C16H8ClN5O4: C 51.98, H 2.18, N 18.94; found C 52.28, H 2.22, N 19.06.  
4.1.3.4. 2-[2-(5(6)-methyl)benzimidazolyl)-3-(2-chloro-5-nitrophenyl)acrylonitrile 20  
 Compound 20 was prepared from 14 (0.50 g,  2.9 mmol) and 2-chloro-5-nitro-
benzaldehyde (0.54 g,  2.9 mmol) in absolute ethanol (20 ml) after refluxing for 1 hour and 
recrystallization from ethanol to yield 0.39 g (40%) of yellow powder; m.p. 200-203 °C; ; IR 
(diamond) υ/cm-1: 2225, 1633, 1524, 1345;  1H NMR (300 MHz, DMSO-d6): δ = 12.95 (bs, 
NH, 1H), 8.96 (d, J=2.58 Hz, Harom., 1H), 8.45 (s, Harom., 1H), 8.37 (dd, J1=2.62 Hz, J2=8.85 
Hz, Harom., 1H), 7.98 (d, J=8.85 Hz, Harom., 1H), 7.55 (d, J=8.28 Hz, Harom., 1H), 7.44 (s, Harom., 
1H), 7.12 (d, J=8.43 Hz, Harom., 1H); 
13C NMR (75 MHz, DMSO-d6): δ = 146.84 (s), 140.80 
(s), 138.64 (d), 134.60 (s), 132.99 (s), 131.99 (d), 131.97 (s), 126.95 (d), 124.94 (d), 124.77 
(d), 119.65 (d), 115.41 (s), 112.98 (s), 111.86 (d), 109.47 (s), 21.97 (d); elemental analysis 
calcd. (%) for C17H11ClN4O2: C 60.28, H 3.27, N 16.54; found C 60.44, H 3.56, N 16.77. 
 
4.1.4. General method for preparation of compounds 6-7 and 21-24 
 Compounds 4-5 and 17-20 were dissolved in 1-4 ml of sulfolane and reaction mixture 
was heated for ½ - 1.5 hours at 280 °C. The cooled mixture was poured into water (25 ml) and 
the resulting product was filtered off and recrystallizated from ethanol to obtain 
benzimidazo[1,2-a]quinolines 4-5 and 17-20.  
4.1.4.1. 3-nitro-benzimidazo[1,2-a]quinoline 6  
 Compound 6 was prepared using above described method from compound 4 (0.50 g, 
1.16 mmol) in sulfolane (3 ml) after 1.5 hours to obtain a brown powder (0.42 g, 95 %). mp 
276-278 °C; IR (diamond) υ/cm-1: 1609, 1545, 1506; 1H NMR (600 MHz, DMSO-d6): δ = 
9.05 (d, J=2.64 Hz, Harom., 1H), 9.01 (d, J=9.30 Hz, Harom., 1H), 8.73 (d, J=8.64 Hz, Harom., 1H), 
8.56 (dd, J1=2.70 Hz, J2=9.24 Hz, Harom., 1H), 8.19 (d, J=9.54 Hz, Harom., 1H), 7.99 (dd, 
J1=1.74 Hz, J2=7.14 Hz, Harom., 1H), 7.83 (d, J=9.54 Hz, Hkinol., 1H), 7.62 (dt, J1=1.80 Hz, 
J2=7.40 Hz, Harom., 1H), 7.59 (dt, J1=1.50 Hz, J2=7.48 Hz, Harom., 1H);  
13C NMR (75 MHz, 
DMSO-d6): δ = 148.14 (s), 144.87 (s), 143.45 (s), 138.86 (s), 131.69 (d), 130.67 (s), 125.68 
(d), 125.59 (d), 124.79 (d), 124.00 (d), 123.64 (s), 120.76 (d), 119.91 (d), 117.29 (d), 115.20 
(d); elemental analysis calcd. (%) for C15H9N3O2: C 68.44, H 3.45, N 15.96; found C 68.66, H 
3.70, N 16.23.  
4.1.4.2. 3,8(9)-dinitro-benzimidazo[1,2-a]quinoline 7 
 Compound 7 was prepared using above described method from compound 5 (0.35 g, 
1.02 mmol) in sulfolane (1 ml) after 45 minutes to obtain a brown powder (0.05 g, 15 %). mp 
>300 °C; ; IR (diamond) υ/cm-1: 3065, 1614, 1513, 1335;  1H NMR (300 MHz, DMSO-d6): δ 
= 9.42 (s, Harom., 1H), 9.07 (dd, J1=2.40 Hz, J2=8.31 Hz, Harom., 2H), 8.98 (dd, J1=3.03 Hz, 
J2=9.60 Hz, Harom., 2H), 8.89 (d, J=9.24 Hz, Harom., 1H), 8.74 (s, Harom., 1H), 8.64 (dd, J1=2.52 
Hz, J2=9.27 Hz, Harom., 1H), 8.55 (dd, J1=2.25 Hz, J2=8.97 Hz, Harom., 1H), 8.45 (dd, J1=1.61 
Hz, J2=9.05 Hz, Harom., 1H), 8.35 (d, J=9.75 Hz, Harom., 2H), 8.26 (d, J=9.69 Hz, Harom., 1H), 
8.10 (d, J=8.85 Hz, Harom., 1H), 7.90 (d, J=9.90 Hz, Harom., 1H), 7.86 (d, J=9.78 Hz, Harom., 
1H); 13C NMR (75 MHz, DMSO-d6): not enough soluble; elemental analysis calcd. (%) for 
C15H8N4O4: C 58.45, H 2.62, N 18.18; found C 58.67, H 2.89, N 18.43.  
4.1.4.3. 3-nitro-6-cyano-benzimidazo[1,2-a]quinoline 21 
 Compound 21 was prepared using above described method from compound 17 (0.50 
g, 1.54 mmol) in sulfolane (2.5 ml) after 1.5 hours to obtain a brown powder (0.43 g, 97 %). 
mp >300 °C; IR (diamond) υ/cm-1: 2239, 1510, 1334; 1H NMR (600 MHz, DMSO-d6): δ = 
9.08 (d, J=2.67 Hz, Harom., 1H), 8.98 (d, J=8.90 Hz, Harom., 1H), 8.96 (s, Harom., 1H), 8.72 (d, 
J=8.95 Hz, Harom., 1H), 8.63 (dd, J1=2.70 Hz, J2=9.00 Hz, Harom., 1H), 8.08 – 8.05 (m, Harom., 
1H), 7.67 – 7.64 (m, Harom., 2H);  13C NMR (75 MHz, DMSO-d6): δ = 144.52 (s), 143.79 (s), 
143.23 (s), 140.04 (d), 139.09 (s), 130.41 (s), 127.12 (d), 126.47 (d), 125.90 (d), 124.48 (d), 
121.34 (s), 120.69 (d), 117.23 (d), 114.85 (d), 114.82 (s), 103.42 (s); elemental analysis calcd. 
(%) for C16H8N4O2: C 66.67, H 2.80, N 19.44; found C 66.89, H 2.94, N 19.67. 
 
4.1. 4.4. 8(9)-nitro-6-cyano-benzimidazo[1,2-a]quinoline 22 
 Compound 22 was prepared using above described method from compound 18 (1.50 
g, 4.62 mmol) in sulfolane (4 ml) after 1 hour to obtain a brown powder (0.28 g, 31 %). mp 
240-245 °C; IR (diamond) υ/cm-1: 3060, 2233, 1517, 1338; 1H NMR (300 MHz, DMSO-d6): 
δ = 8.97 (s, NHarom., 1H), 8.93 (s, Harom, 1H), 8.93 (s, Harom, 1H), 8.85 (d, J=8.70 Hz, Harom, 
1H), 8.84 (d, J=8.70 Hz, Harom, 1H), 8.81 (d, J=2,28 Hz, Harom, 1H), 8.34 (dd, J1=9.24 Hz, 
J2=2.34 Hz, Harom, 1H), 8.18 (7.70 (d, J=8.76 Hz, Harom, 1H),), 8.17 (dd, J1=7.82 Hz, J2=1.27 
Hz, Harom, 2H), 8.04 (td, J1=7.44 Hz, J2=1.38 Hz, Harom, 1H), 8.03 (td, J1=7.46 Hz, J2=1.38 
Hz, Harom, 1H), 7.75-7.70 (m, Harom, 2H), 7.62-7.56 (m, Harom, 2H);  
13C NMR (150 MHz, 
DMSO-d6): δ = 147.36 (s), 144.39 (s), 143.13 (s), 142.49 (d), 137.05 (d), 134.23 (s), 134.01 
(d), 132.16 (d), 132.02 (d), 131.49 (d), 130.86 (s), 130.81 (s), 130.46 (d), 130.13 (d), 129.75 
(d), 127.82 (d), 127.58 (d), 126.84 (s), 126.07 (d), 121.45 (s), 117.93 (d), 116.11 (d), 115.64 
(d), 115.51 (d), 114.88 (s), 101.05 (s); elemental analysis calcd. (%) for C16H8N4O2: C 66.67, 
H 2.80, N 19.44; found C 66.90, H 2.88, N 19.78. 
 
4.1.4.5. 3,8(9)-dinitro-6-cyano-benzimidazo[1,2-a]quinoline 23 
 Compound 23 was prepared using above described method from compound 19 (0.25 
g, 0.68 mmol) in sulfolane (1 ml) after 45 minutes to obtain a brown powder (0.03 g, 15 %). 
mp >300 °C; ; IR (diamond) υ/cm-1: 2250, 1611, 1519, 1441, 1346; 1H NMR (300 MHz, 
DMSO-d6): δ = 9.42 (d, J=1.83 Hz, Harom., 1H), 9.13-9.09 (m, Harom., 3H), 9.06 (s, Harom., 1H), 
9.03 (d, J=8.82 Hz, Harom., 1H), 9.00 (d, J=9.03 Hz, Harom., 1H), 8.90 (d, J=9.30Hz, Harom., 
1H), 8.86 (d, J=2.25 Hz, Harom., 1H), 8.72 (dd, J1=2.55 Hz, J2=9.36 Hz, Harom., 1H), 8.65 (dd, 
J1=2.60 Hz, J2=9.29 Hz, Harom., 1H), 8.49 (dd, J1=1.83 Hz, J2=9.03 Hz, Harom., 1H), 8.40 (dd, 
J1=2.28 Hz, J2=9.21 Hz, Harom., 1H), 8.22 (d, J=9.03 Hz, Harom., 1H); 
13C NMR (150 MHz, 
DMSO-d6): δ = 159.29 (s), 148.30 (s), 147.71 (s), 144.31 (s) 144.27 (s), 143.83 (s), 143.69 
(s), 142.80 (d), 142.21 (d), 138.90 (s), 138.80 (s), 134.50 (s), 131.15 (s), 129.96 (s), 128.37 
(d), 127.68 (d), 127.11 (d), 127.01 (d), 125.39 (s), 122.13 (s), 122.00 (s), 121.61 (d), 121.33 
(d), 119.25 (d), 118.28 (d), 117.99 (d), 116.55 (d), 116.01 (d), 114.75 (s), 111.85 (d), 103.68 
(s); elemental analysis calcd. (%) for C16H7N5O4: C 57.66, H 2.12, N 21.01; found C 57.86, H 
2.33, N 21.28.  
4.1.4.6. 3-nitro-8(9)-methyl-6-cyano-benzimidazo[1,2-a]quinoline 24 
 Compound 24 was prepared using above described method from compound 20 (0.25 
g, 0.74 mmol) in sulfolane (1 ml) after 50 minutes to obtain a green powder (0.13 g, 56 %). 
mp 250-254 °C; ; IR (diamond) υ/cm-1: 2236, 1611, 1521, 1387; 1H NMR (300 MHz, DMSO-
d6): δ = 8.90 (d, J=2.43 Hz, Harom., 1H), 8.88 (d, J=2.67 Hz, Harom., 1H), 8.74 (s, Harom., 1H), 
8.69 (d, J=8.22 Hz, Harom., 1H), 8.86 (d, J=8.85 Hz, Harom., 1H), 8.66 (d, J=8.34 Hz, Harom., 
1H), 8.47-8.41 (m, Harom., 2H), 8.31 (d, J=8.37 Hz, Harom., 1H), 8.24 (s, Harom., 1H), 7.78 (d, 
J=8.28 Hz, Harom., 1H), 7.67 (d, J=2.64 Hz, Harom., 1H), 7.36 (d, J=8.21 Hz, Harom., 1H), 7.30 
(d, J=8.22 Hz, Harom., 1H), 2.56 (s, CH3, 3H), 2.51 (s, CH3, 3H); 
13C NMR (150 MHz, 
DMSO-d6): δ = 144.17 (s), 143.97 (s), 143.69 (s), 142.69 (s), 142.88 (s), 142.48 (s), 139.32 
(d), 139.06 (d), 138.64 (s), 138.48 (s), 135.54 (s), 134.45 (s), 130.21 (s), 130.16 (s), 128.09 
(s), 127.26 (d), 126.79 (d), 126.66 (d), 126.21 (d), 126.14 (d), 125.78 (d), 121.04 (s), 120.89 
(s), 120.03 (d), 119.98 (d), 116.83 (d), 116.74 (d), 114.64 (s), 114.19 (d), 114.02 (d), 103.23 
(s), 103.07 (s), 21.55 (d), 21.07 (d); elemental analysis calcd. (%) for C17H10N4O2: C 67.55, H 
3.33, N 18.53; found C 67.89, H 3.56, N 18.83. 
 
4.1.5. General method for the synthesis of amino-benzimidazo[1,2-a]quinoline 
derivatives 8-9 and 25-28 
 Corresponding nitro-benzimidazo[1,2-a]quinoline derivatives 6-7 and 21-24 and 
solution of SnCl2x2H2O in MeOH and concentrated HCl were refluxed for ½ - 1.5 hours. 
After cooling, the recation mixture was evaporated under vacuum and dissolved in water (50 
ml). The resulting solution was treated with 20 % NaOH to pH = 14. Resulting product was 
filtered off and washed with water to obtain amino-benzimidazo[1,2-a]quinolines. 
4.1.5.1. 3-amino-benzimidazo[1,2-a]quinoline 8  
 Compound 8 was prepared using above described method from compound 6 (0.40 g, 
1.52 mmol), SnCl2 x 2H2O (2.90 g, 12.62 mmol), HClconc. (5.3 ml) and H2O (5.3 ml) to a 
green powder (0.25 g, 71 %). mp 240-243 °C; IR (diamond) υ/cm-1: 3192, 1612, 1562; 1H 
NMR (300 MHz, DMSO-d6): δ = 8.59 (d, J=7.47 Hz, Harom., 1H), 8.52 (d, J=8.91 Hz, Harom., 
1H), 7.85 (d, J=7.41 Hz, Harom., 1H), 7.73 (d, J=9.51 Hz, Harom. 1H), 7.73 (d, J=9.48 Hz, Harom., 
1H), 7.47-7.40 (m, Harom., 2H), 7.13 (dd, J1=2.52 Hz, J2=8.88 Hz, Harom., 1H), 7.07(d, J=2.52 
Hz, Harom.,1H), 5.45 (bs, NH2, 2H);  
13C NMR (75 MHz, DMSO-d6): δ = 147.44 (s), 146.18 
(s), 144.59 (s), 131.89 (d), 130.57 (s), 126.78 (s), 124.71 (s), 124.09 (d), 122.37 (d), 120.02 
(d), 118.22 (d), 117.36 (d), 116.78 (d), 114.72 (d), 111.90 (d); elemental analysis calcd. (%) 
for C15H11N3: C 72.56, H 4.87, N 22.57; found C 72.87, H 4.98, N 22.66.  
 
4.1.5.2. 3,8(9)-diamino-benzimidazo[1,2-a]quinoline 9  
 Compound 9 was prepared using above described method from compound 7 (0.14 g, 
0.45 mmol), SnCl2 x 2H2O (1.70 g, 7.54 mmol), HClconc. (3.1 ml) and MeOH (3.1 ml) to a 
brown powder (0.03 g, 28 %). mp >300 °C; ; IR (diamond) υ/cm-1: 2917, 1633, 1631, 1438; 
1H NMR (300 MHz, DMSO-d6): δ = 8.35 (d, J=8.85 Hz, Harom., 1H), 8.22 (d, Hz, J=8.82 Hz, 
Harom., 2H), 7.68 (d, J=1.53 Hz, Harom., 1H), 7.60 (d, J=9.45 Hz, Harom., 1H), 7.53 (d, J=8.67 
Hz, Harom., 1H), 7.49 (d, J=9.63 Hz, Harom., 1H), 7.38 (d, J=8.76 Hz, Harom., 1H), 7.35 (d, 
J=9.69 Hz, Harom., 1H), 7.11 (dd, J1=2.70 Hz, J2=9.09 Hz, Harom., 1H), 7.07 (dd, J1=3.03 Hz, 
J2=9.37 Hz, Harom., 1H), 7.03-7.00 (m, Harom., 2H), 6.91 (d, J=2.01 Hz, Harom., 1H), 6.83 (dd, 
J1=1.68 Hz, J2=8.67 Hz, Harom., 1H), 6.77 (dd, J1=2.01 Hz, J2=8.82 Hz, Harom., 1H), 5.33 (bs, 
NH2, 8H); 
13C NMR (150 MHz, DMSO-d6): δ = 146.50 (s), 146.21 (s), 145.89 (s), 145.78 (s), 
145.55 (s), 145.26 (s), 144.81 (s), 136.45 (s), 131.56 (s), 130.99 (d), 129.45 (d), 127.01 (s), 
126.53 (s), 124.91 (s), 124.60 (s), 122-27 (s), 120.12 (d), 118.63 (d), 117.60 (d), 117.19 (d), 
116.49 (d), 116.16 (d), 116.96 (d), 114.99 (d), 114.16 (d), 112.72 (d), 112.01 (d), 111.53 (d), 
101.24 (d), 97.56 (d); elemental analysis calcd. (%) for C15H12N4: C 77.23, H 4.75, N 18.01; 
found C 77.51, H 4.98, N 18.32. 
4.1.5.3. 3-amino-6-cyano-benzimidazo[1,2-a]quinoline 25 
 Compound 25 was prepared using above described method from compound 21 (0.20 
g, 0.69 mmol), SnCl2 x 2H2O (1.30 g, 5.76 mmol), HClconc. (2.0 ml) and MeOH (2.0 ml) to a 
yellow powder (0.12 g, 67 %). mp >300 °C; IR (diamond) υ/cm-1: 3335, 2239, 1568; 1H NMR 
(300 MHz, DMSO-d6): δ = 8.67 (d, J=9.00 Hz, Harom., 1H), 8.64 (s, Harom., 1H), 8.61 (d, 
J=8.99 Hz, Harom., 1H), 7.97 (d, J=7.53 Hz, Harom., 1H), 7.59 – 7.49 (m, Harom., 2H), 7.31 (dd, 
J1=2.52 Hz,  J2=9.00 Hz, Harom., 1H), 7.16 (d, J=2.55 Hz, Harom., 1H), 5.70 (šs, NH2, 2H);  13C 
NMR (75 MHz, DMSO-d6): δ = 146.32 (s), 143.78 (s), 143.59 (s), 140.42 (d), 130.25 (s), 
127.06 (s), 124.51 (d), 122.94 (d), 122.56 (s), 121.11 (d), 120.00 (d), 116.70 (d), 115.72 (s), 
114.54 (d), 100.67 (s); elemental analysis calcd. (%) for C16H10N4: C 74.40, H 3.90, N 21.69; 
found C 74.64, H 4.11, N 21.76.   
4.1.5.4. 8(9)-amino-6-cyano-benzimidazo[1,2-a]quinoline 26 
 Compound 26 was prepared using above described method from compound 22 (0.25 
g, 0.87 mmol), SnCl2 x 2H2O (1.63 g, 7.20 mmol), HClconc. (3.0 ml) and MeOH (3.0 ml) to a 
brown powder (0.21 g, 89 %). mp 195-199 °C; IR (diamond) υ/cm-1: 3211, 2229, 1504, 1448; 
1H NMR (300 MHz, DMSO-d6): δ = 8.72 (d, J=8.70 Hz, Harom, 1H), 8.69 (s, Harom, 1H), 8.57 
(s, Harom, 1H), 8.54 (d, J=8.88 Hz, Harom, 1H), 8.39 (d, J=9.00 Hz, Harom, 1H), 8.10 (t, J=7.86 
Hz, Harom, 1H), 8.09 (t, J=7.88 Hz, Harom, 1H), 7.96 (t, J=8.40 Hz, Harom, 1H), 7.95 (t, J=8.44 
Hz, Harom, 1H),  7.94 (s, Harom, 1H), 7.70 (d, J=8.76 Hz, Harom, 1H), 7.62 (t, J=7.53 Hz, Harom, 
1H), 7.60 (t, J=7.54 Hz, Harom, 1H), 7.03 (d, J=2.04 Hz, Harom, 1H), 6.97 (dd, J1=8.74 Hz, 
J2=1.76 Hz, Harom, 1H), 6.92 (dd, J1=8.97 Hz, J2=2.16 Hz, Harom, 1H), 5.47 (bs, NH2, 2H), 
5.39 (bs, NH2, 2H);  
13C NMR (75 MHz, DMSO-d6): δ = 150.67 (s), 147.62 (s), 147.20 (s), 
146.26 (s), 144.57 (s), 139.14 (d), 138.14 (d), 138.10 (d), 136.52 (s), 136.19 (s), 135.82 (s), 
133.81 (d), 133.16 (d), 132.26 (s), 131.46 (d), 131.38 (d), 125.14 (d), 124.96 (d), 123.07 (s), 
121.91 (s), 121.34 (s), 121.10 (d), 116.20 (s), 116.09 (s), 115.94 (d), 115.48 (d), 115.38 (d), 
113.96 (d), 102.08 (s), 101.92 (d), 101.05 (s), 97.30 (d); elemental analysis calcd. (%) for 
C16H10N4: C 74.40, H 3.90, N 21.69; found C 74.58, H 4.14, N 21.92.  
4.1.5.5. 3,8(9)-diamino-6-cyano-benzimidazo[1,2-a]quinoline 27 
 Compound 27 was prepared using above described method from compound 23 (0.09 
g, 0.27 mmol), SnCl2 x 2H2O (1.01 g, 4.49 mmol), HClconc. (1.9 ml) and MeOH (1.9 ml) to a 
brown powder (0.08 g, 81 %). mp >300 °C; ; IR (diamond) υ/cm-1: 2236, 1633, 1564, 1446, 
1360; 1H NMR (300 MHz, DMSO-d6): δ = 8.46 (s, Harom., 1H), 8.44 (d, J=9.15 Hz, Harom., 
1H), 8.36 (s, Harom., 1H), 8.29 (dd, J1=2.60 Hz, J2=8.95 Hz, Harom., 2H), 7.70 (s, Harom., 1H), 
7.63 (d, J=8.67 Hz, Harom., 1H), 7.26 (dd, J1=2.51 Hz, J2=9.20 Hz, Harom., 1H), 7.22 (dd, 
J1=2.71 Hz, J2=8.93 Hz, Harom., 1H), 7.11 (s, Harom., 1H), 7.10 (s, Harom., 1H), 6.98 (s, Harom., 
1H), 6.91 (dd, J1=1.62 Hz, J2=8.78 Hz, Harom., 1H), 6.86 (dd, J1=2.19 Hz, J2=8.97 Hz, Harom., 
1H), 5.56 (bs, NH2, 4H), 5.29 (bs, NH2, 4H); 
13C NMR (75 MHz, DMSO-d6): δ = 147.11 (s), 
146.61 (s), 146.40 (s), 146.30 (s), 146.05 (s), 143.84 (s), 141.92 (s), 138.67 (d), 138.01 (d), 
136.23 (s), 131.91 (s), 127.72 (s), 127.47 (s), 123.12 (s), 128.09 (s), 122.70 (s), 121.75 (d), 
120.76 (d), 120.44 (d), 116.70 (d), 116.54 (s), 116.41 (s), 116.28 (d), 115.04 (d), 113.56 (d), 
112.58 (d), 112.02 (d), 101.70 (d), 101.53 (s), 101.41 (d), 100.50 (s), 97.01 (d); elemental 
analysis calcd. (%) for C16H101N5: C 70.32, H 4.06, N 25.63; found C 70.56, H 4.32, N 25.87. 
4.1.5.6. 3-amino-8(9)-methyl-6-cyano-benzimidazo[1,2-a]quinoline 28 
 Compound 28 was prepared using above described method from compound 24 (0.09 
g, 0.30 mmol), SnCl2 x 2H2O (0.56 g, 2.49 mmol), HClconc. (1.0 ml) and MeOH (1.0 ml) to a 
green powder (0.07 g, 85 %). mp >300 °C; ; IR (diamond) υ/cm-1: 2236, 1632, 1567, 1531, 
1448; 1H NMR (300 MHz, DMSO-d6): δ = 8.63 (s, Harom., 1H), 8.60 (s, Harom., 1H), 8.57 (d, 
J=8.45 Hz, Harom., 1H), 8.52 (s, Harom., 1H), 8.48 (d, J=8.45 Hz, Harom., 2H), 8.23 (d, J=8.20 
Hz, Harom., 1H), 8.05 (s, Harom., 1H), 7.82 (d, J=8.18 Hz, Harom., 1H), 7.36 (s, Harom., 1H), 7.39-
7.32 (m, Harom., 3H), 7.15 (d, J=8.20 Hz, Harom., 1H), 5.66 (s, NH2, 2H), 5.55 (s, NH2, 2H), 
2.62 (s, CH3, 3H), 2.53 (s, CH3, 3H); 
13C NMR (150 MHz, DMSO-d6): δ = 163.69 (s), 147.12 
(s), 146.27 (s), 146.03 (s), 144.02 (s), 143.03 (s), 140.75 (s), 139.85 (d), 134.53 (d), 134.40 
(d), 133.90 (s), 132.84 (s), 132.84 (s), 132.42 (s), 130.47 (s), 128.02 (s), 127.06 (s), 126.13 
(d), 125.94 (d), 124.51 (d), 124.18 (d), 123.09 (s), 122.89 (s), 121.21 (d), 120.08 (d), 119.95 
(d), 119.82 (s), 119.55 (d), 119.03 (d), 116.78 (d), 116.28 (d), 115.82 (s), 21.56 (d), 21.13 (d); 
elemental analysis calcd. (%) for C17H12N4: C 74.98, H 4.44, N 20.58; found C 75.32, H 4.67, 
N 20.83. 
 
4.1.6. General method for the synthesis of amino-benzimidazo[1,2-a]quinoline 
hydrochlorides 10-11 and 29-32  
 A stirred suspension of compounds 8-9 and 25-28 in absolute ethanol (5-10 mL) was 
saturated with HCl(g). After 24 hours of stirring small amount of diethylether was added, 
resulting product was filtered off and washed with diethylether to obtain amino-
benzimidazo[1,2-a]quinoline hydrochlorides.  
4.1.6.1. 3-amino-benzimidazo[1,2-a]quinoline hydrochloride 10  
 Compound 10 was prepared using above described method from compound 8 (0.12 g, 
0.52 mmol) to obtain a green powder (0.11 g, 80 %). mp 285-288 °C; IR (diamond) υ/cm-1: 
3026, 2716, 2544, 2492, 1612, 1572; 1H NMR (300 MHz, DMSO-d6): δ = 8.97 (d, J=9.41 Hz, 
Harom., 1H), 8.92 (d, J=9.84 Hz, Harom., 1H), 8.46 (d, J=9.48 Hz, Harom., 1H), 8.04 (d, J=7.98 Hz, 
Harom., 1H), 7.92 (d, J=9.42 Hz, Harom., 1H), 7.83-7.72 (m, Harom., 2H), 7.58 (d, J=9.00 Hz, 
Harom., 1H), 7.56 (bs, Harom., 1H), 5.35 (bs, NH3
+, 3H); 13C NMR (75 MHz, DMSO-d6): δ = 
113.18 (s), 138.48 (d), 132.88 (s), 128.85 (s), 128.80 (s), 128.11 (d), 125.68 (d), 125.56 (s), 
124.38 (d), 124.36 (d), 124.34 (d), 118.85 (d), 116.84 (d), 115.34 (d), 111.91 (d); elemental 
analysis calcd. (%) for C15H12ClN3: C 66.79, H 4.48, N 15.58; found C 66.92, H 4.70, N 
15.81.  
4.1.6.2. 3,8(9)-diamino-benzimidazo[1,2-a]quinoline hydrochloride 11  
 Compound 11 was prepared using above described method from compound 9 (0.10 g, 
0.33 mmol) to obtain a light brown powder (0.11 g, 86 %). mp 270-273 °C; ; IR (diamond) 
υ/cm-1: 2818, 2577, 1630, 1564, 1503; 1H NMR (300 MHz, DMSO-d6): δ = 9.00 (s, Harom., 
1H), 8.91 (d, J=8.94 Hz, Harom., 1H), 8.82 (d, J=9.08 Hz, Harom., 1H), 8.65 (d, J=9.08 Hz, 
Harom., 1H), 8.42 (d, J=9.54 Hz, Harom., 1H), 8.37 (d, J=9.60 Hz, Harom., 2H), 8.01 (d, J=8.73 
Hz, Harom., 1H), 7.87 (d, J=9.33 Hz, Harom., 1H), 7.86 (s, Harom., 1H), 7.84 (d, J=8.74 Hz, 
Harom., 1H), 7.81 (d, J=9.33 Hz, Harom., 1H), 7.78 (d, J=1.76 Hz, Harom., 1H), 7.65(d, J=8.55 
Hz, Harom., 1H), 7.64 (s, Harom., 1H), 7.42 (dd, J1=1.74 Hz, J2=8.60 Hz, Harom., 1H), 7.79 (bs, 
NH3
+, 12H); 13C NMR (150 MHz, DMSO-d6): δ =144.17 (s), 143.44 (s), 136.48 (d), 136.40 
(d), 134.98 (s), 129.73 (s), 129.70 (s), 129.63 (s), 129.60 (s), 129.58 (s), 128.48 (s), 125.02 
(d), 124.97 (d), 124.80 (s), 124.71 (s), 124.67 (s), 124.56 (s), 124.26 (d), 121.39 (d), 119.77 
(d), 119.73 (d), 118.07 (d), 117.73 (d), 117.03 (d), 116.85 (d), 116.62 (d), 112.94 (d), 112.32 
(d), 108.84 (d); elemental analysis calcd. (%) for C15H14Cl2N4: C 56.09, H 4.39, N 17.44; 
found C 56.33, H 4.52, N 17.48.  
4.1.6.3. 3-amino-6-cyano-benzimidazo[1,2-a]quinoline hydrochloride 29  
 Compound 29 was prepared using above described method from compound 25 (0.10 
g, 0.39 mmol) to obtain a yellow powder (0.05 g, 44 %). mp >288 °C; IR (diamond) υ/cm-1: 
3321, 3142, 3045, 2812, 2582, 2050, 1664, 1579; 1H NMR (300 MHz, DMSO-d6): δ = 9.16 
(s, Harom., 1H), 9.02 (d, J=8.58 Hz, Harom., 1H), 8.99 (s, Harom., 1H), 8.91 (d, J=8.38 Hz, Harom., 
1H), 8.12 (d, J=7.74 Hz, Harom., 1H), 7.76 (d, J=7.64 Hz, Harom., 1H), 7.66-7.57 (m, Harom., 
2H), 5.50 (šs, NH3+, 3H);  13C NMR (75 MHz, DMSO-d6): δ = 164.67 (s), 163.19 (s), 147.59 
(s), 142.17 (d), 139.81 (s), 132.61 (s), 129.12 (s), 128.44 (d), 128.24 (s), 126.99 (d), 126.02 
(d), 124.61 (d), 118.68 (d), 118.11 (d), 116.09 (d), 112.97 (s); elemental analysis calcd. (%) 
for C16H11ClN4: C 65.20, H 3.76, N 19.01; found C 65.43, H 3.94, N 19.32. 
 
4.1.6.4. 8(9)-amino-6-cyano-benzimidazo[1,2-a]quinoline  hydrochloride 30  
 Compound 30 was prepared using above described method from compound 26 (0.05 
g, 0.19 mmol) to obtain a light brown powder (0.05 g, 99 %). mp 271-275 °C; IR (diamond) 
υ/cm-1:2786, 2564, 1976, 1675, 1502; 1H NMR (300 MHz, DMSO-d6): δ = 8.96 (s, Harom, 
1H), 8.94 (d, J=8.78 Hz, Harom, 1H), 8.89 (s, Harom, 1H), 8.83 (d, J=9.06 Hz, Harom, 1H), 8.78 
(s, Harom, 1H), 8.68 (d, J=8.52 Hz, Harom, 1H), 8.31 (t, J=7.80 Hz, Harom, 1H), 8.80 (t, J=77 Hz, 
Harom, 1H), 8.20 (s, Harom, 1H), 8.07 (d, J=8.73 Hz, Harom, 1H),  8.04 (d, J=8.73 Hz, Harom, 
1H), 7.76 (d, J=8.13 Hz, Harom, 1H), 7.74 (d, J=8.04 Hz, Harom, 1H), 7.53 (d, J=8.67 Hz, Harom, 
1H), 7.12 (d, J=7.65 Hz, Harom, 1H), 7.36 (d, J=7.92 Hz, Harom, 1H), 3.92 (bs, NH3
+, 3H), 3.90 
(bs, NH3
+, 3H);  
13C NMR (150 MHz, DMSO-d6): δ = 163.76 (s), 163.46 (s), 151.70 (s), 
149.61 (s), 145.70 (s), 145.44 (s), 144.93 (s), 143.15 (s), 138.57 (s), 136.68 (d), 136.46 (d), 
134.88 (s), 134.53 (s), 133.31 (d), 132.87 (d), 131.87 (d), 131.68 (d), 129.29 (s), 126.18 (d), 
126.15 (d), 125.90 (d), 122.18 (s), 122.16 (s), 120.52 (d), 119.41 (d), 119.15 (s), 117.89 (d), 
117.89 (d), 116.44 (d), 116.20 (d), 115.16 (d); elemental analysis calcd. (%) for C16H11ClN4: 
C 65.20, H 3.76, N 19.01; found C 65.43, H 3.89, N 19.25.  
4.1.6.5. 3,8(9)-diamino-6-cyano-benzimidazo[1,2-a]quinoline hydrochloride 31 
 Compound 31 was prepared using above described method from compound 27 (0.05 
g, 0.18 mmol) to obtain a brown powder (0.04 g, 73 %). mp >300 °C; ; IR (diamond) υ/cm-1: 
2577, 2242, 1626, 1566, 1449; 1H NMR (300 MHz, DMSO-d6): δ = 8.94 (s, Harom., 1H), 8.85 
(s, Harom., 1H), 8.79 (d, J=8.76 Hz, Harom., 1H), 8.78 (d, J=8.85 Hz, Harom., 1H), 8.48 (d, J=8.82 
Hz, Harom., 1H), 8.17 (s, Harom., 1H), 8.03 (d, J=8.70 Hz, Harom., 1H), 7.99 (s, Harom., 1H), 7.84 
(d, J=8.10 Hz, Harom., 1H), 7.81 (d, J=8.86 Hz, Harom., 2H), 7.79 (d, J=8.04 Hz, Harom., 1H), 
7.62 (d, J=8.82 Hz, Harom., 1H), 7.57 (d, J=8.80 Hz, Harom., 1H), 5.48 (bs, NH3
+, 12H); 13C 
NMR (75 MHz, DMSO-d6): δ = 145.70 (s), 145.43 (s), 143.98 (s), 142.76 (s), 141.36 (d), 
141.11 (d), 134.51 (s), 132.18 (s), 131.91 (s), 130.27 (s), 130.20 (s), 130.16 (s), 129.74 (s), 
129.71 (s), 128.75 (s), 126.58 (d), 125.94 (d), 125.91 (d), 122.75 (s), 122.62 (s), 121.31 (d), 
120.86 (d), 119.02 (d), 117.69 (d), 116.71 (d), 116.19 (d), 115.57 (s), 114.39 (d), 109.93 (d), 
102.20 (s), 101.94 (s); elemental analysis calcd. (%) for C16H13Cl2N5: C 55.51, H 3.78, N 
20.23; found C 55.76, H 3.93, N 20.44. 
4.1.6.6. 3-amino-8(9)-methyl-6-cyano-benzimidazo[1,2-a]quinoline  hydrochloride 32 
 Compound 32 was prepared using above described method from compound 28 (0.04 
g, 0.15 mmol) to obtain a green powder (0.03 g, 74 %). mp >300 °C; ; IR (diamond) υ/cm-1: 
2846, 2582, 2340, 1677, 1625; 1H NMR (300 MHz, DMSO-d6): δ = 9.18 (s, Harom., 1H), 9.07 
(d, J=8.44 Hz, Harom., 1H), 8.96 (d, J=8.97 Hz, Harom., 1H), 8.91 (d, J=8.99 Hz, Harom., 1H), 
8.76 (d, J=8.64 Hz, Harom., 1H), 8.71 (s, Harom., 1H), 8.21 (s, Harom., 1H), 7.96 (d, J=8.34 Hz, 
Harom., 1H), 7.87 (s, Harom., 1H), 7.76-7.70 (m, Harom., 3H), 7.56 (d, J=8.70 Hz, Harom., 1H), 
7.50 (d, J=8.20 Hz, Harom., 1H), 5.01 (bs, NH3
+, 6H), 2.65 (s, CH3, 3H), 2.57 (s, CH3, 3H) ; 
13C NMR (150 MHz, DMSO-d6): δ = 164.18 (s), 164.14 (s), 162.71 (s), 162.38 (s), 137.12 (s), 
137.06 (s), 136.71 (d), 136.12 (s), 135.15 (s), 135.10 (s), 132.16 (s), 129.94 (s), 129.36 (d), 
128.45 (s), 128.34 (d), 127.79 (s), 127.11 (d), 126.35 (d), 126.31 (s), 125.62 (d), 123.90 (s), 
123.88 (s), 123.45 (s), 123.13 (s), 118.36 (d), 118.17 (d), 117.95 (d), 117.63 (d), 115.79 (d), 
115.60 (d), 115.24 (d), 115.13 (d), 21.43 (d), 21.21 (d); elemental analysis calcd. (%) for 
C17H13ClN4: C 66.13, H 4.24, N 18.15; found C 66.37, H 4.36, N 18.42.  
4.2. Spectroscopy 
The electronic absorption spectra were recorded on Varian Cary 50 and Varian Cary 
100 Bio spectrometer, CD spectra on Jasco J815, in all cases using quartz cuvettes (1 cm).  
Fluorescence emission spectra were recorded on Varian Eclipse fluorimeter (quartz cuvettes, 
1 cm), from 350 – 600 nm. The sample concentration in fluorescence measurements had an 
optical absorbance below 0.05 at the excitation wavelength. Under the experimental 
conditions used the absorbance and fluorescence intensities of studied compounds were 
proportional to their concentrations, while none of studied compounds showed CD spectrum. 
The measurements were performed in the aqueous buffer solution (pH = 7.0; sodium 
cacodylate buffer, I = 0.05 mol dm-3).  
4.3. Interactions with DNA 
The calf thymus DNA (ct-DNA) was purchased from Aldrich, dissolved in the sodium 
cacodylate buffer, I = 0.05 mol dm-3, pH = 7.0, additionally sonicated and ﬁltered through a 
0.45 µm ﬁlter and the concentration of corresponding solution determined spectroscopicaly as 
the concentration of phosphates.25 The measurements were performed in the aqueous buffer 
solution (pH = 7.0; sodium cacodylate buffer, I = 0.05 mol dm-3). Spectroscopic titrations 
were performed by adding portions of polynucleotide solution into the solution of the studied 
compound. The stability constant (Ks) and [bound compound]/[polynucleotide phosphate] 
ratio (n) were calculated according to the Scatchard equation by non-linear least-square 
fitting, a giving excellent correlation coefficients (> 0.999) for obtained values for Ks and n. 
Thermal denaturation curves for ct-DNA and its complexes with studied compounds were 
determined as previously described by following the absorption change at 260 nm as a 
function of temperature. The absorbance of the ligand was subtracted from every curve, and 
the absorbance scale was normalized. Obtained Tm values are the midpoints of the transition 
curves, determined from the maximum of the first derivative or graphically by a tangent 
method. Given Tm values were calculated subtracting Tm of the free nucleic acid from Tm of 
complex. Every Tm value here reported was the average of at least two measurements, the 
error in Tm is  0.5 °C.  
4.4. Antitumor evaluation assay 
The experiments were carried out on five human cell lines, which are derived from 
four cancer types. The following cell lines were used: SW 620 and HCT 116 (colon 
carcinoma), H 460 (lung carcinoma), MCF-7 (breast carcinoma) and MOLT-4 (T-
lymphoblast leukemia). MCF-7, SW 620, HCT 116 and H 460 cells were cultured as 
monolayers and maintained in Dulbecco's modified Eagle medium (DMEM) while MOLT-4 
cells were cultured in suspension in RPMI medium, both supplemented with 10% fetal bovine 
serum (FBS), 2mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin in a 
humidified atmosphere with 5% CO2 at 37˚C. 
 The growth inhibition activity was assessed as described previously [7,8,15,16,20]. The panel 
cell lines were inoculated onto a series of standard 96-well microtiter plates on day 0, at 
1×104 to 3×104 cells/mL, depending on the doubling times of a specific cell line. Test agents 
were then added in ten-fold dilutions (10-8 to 10-4 M) and incubated for further 72 h. Working 
dilutions were freshly prepared on the day of testing. After 72 h of incubation the cell growth 
rate was evaluated by performing the MTT assay, which detects dehydrogenise activity in 
viable cells. The absorbance (A) was measured on a microplate reader at 570 nm. The 
absorbance is directly proportional to the number of living, metabolically active cells. The 
percentage of growth (PG) of the cell lines was calculated according to one or the other of the 
following two expressions: 
If (mean Atest – mean Atzero) ≥ 0, then PG = 100 × (mean Atest – mean Atzero) / (mean Actrl – 
meanAtzero). 
If (mean Atest – mean Atzero) < 0, then: PG = 100 × (mean Atest – mean Atzero) / Atzero, where the 
mean Atzero is the average of optical density measurements before exposure of cells to the test 
compound, the mean Atest is the average of optical density measurements after the desired 
period of time and the mean Actrl is the average of optical density measurements after the 
desired period of time with no exposure of cells to the test compound. The results are 
expressed as IC50, which is the concentration necessary for 50% of inhibition. The IC50 values 
for each compound are calculated from concentration-response curves using linear regression 
analysis by fitting the test concentrations that give PG values above and below the reference 
value (i.e. 50%). If however, for all of the tested concentrations produce PGs exceeding the 
respective reference level of effect (e.g. PG value of 50), then the highest tested concentration 
is assigned as the default value, which is preceded by a ">" sign. Each test was performed in 
quadruplicate in at least two individual experiments. 
 
4.5. Cell Cycle Analysis.  
 Tumor cells (2  105) were seeded per well into a 6-well plate. After 24 hours the tested 
compounds were added at various concentrations (as shown in the Results section). After the 
desired length of time the attached cells were trypsinized, combined with floating cells, 
washed with phosphate buffer saline (PBS), fixed with 70% ethanol and stored at -20ºC. 
Immediately before the analysis, the cells were washed with PBS and stained with 50µg/ml of 
propidium iodide (PI) with the addition of 0.2 µg/µl of RNAse A. The stained cells were then 
analyzed with Becton Dickinson FACScalibur (Becton Dickenson) flow cytometer (20 000 
counts were measured). The percentage of the cells in each cell cycle phase was determined 
using the ModFit LT™ software (Verity Software House) based on the DNA histograms. The 
tests were performed in duplicates and repeated at least twice. 
 
4.6. Intracellular distribution of compounds 11 and 29 
H 460 cells were seeded on round microscopic cover slips placed in 24-well-plates (100 000 
cells/well) and grown at 37°C for 24 h in DMEM, as described above. Cells were then incubated with 
compounds 11 and 29 both in 100 µM final concentration for 120 min and 20 µM final concentration 
for 24 h. Cover slips were rinsed twice with PBS, placed on the microscopic slides and immediately 
analysed. The uptake and intracellular distribution of tested chemicals were analysed under the 
fluorescence microscope (Olympus BX51) and recorded with Olympus DP70 Digital Camera. 
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